Patents Assigned to Epizyme, Inc.
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 12251386
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: September 29, 2022
    Date of Patent: March 18, 2025
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Aryl-or heteroaryl-substituted benzene compounds
    Patent number: 12168015
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: March 15, 2024
    Date of Patent: December 17, 2024
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • Method for treating cancer
    Patent number: 12168014
    Abstract: The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: December 17, 2024
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Heike Keilhack, Brett Truitt, Yuta Suzuki, Tsukasa Murase, Futoshi Shikata
  • Aryl-OR heteroaryl-substituted benzene compounds
    Patent number: 12168016
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: March 15, 2024
    Date of Patent: December 17, 2024
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • Aryl-or heteroaryl-substituted benzene compounds
    Patent number: 12161645
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: March 15, 2024
    Date of Patent: December 10, 2024
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • Methods of treating cancer
    Patent number: 12162865
    Abstract: The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: December 10, 2024
    Assignee: Epizyme, Inc.
    Inventors: Sarah K. Knutson, Natalie Warholic, Heike Keilhack
  • Substituted indoles and methods of use thereof
    Patent number: 12116358
    Abstract: Compounds of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1e, G1, G2, Q1, Q2, Q3, and (II) are defined as set forth in the specification, as are uses of compounds of Formula I to treat a disease, disorder, or condition such as cancer in a subject.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: October 15, 2024
    Assignee: Epizyme, Inc.
    Inventors: John Lampe, John Campbell, Kenneth Duncan, Megan Alene Cloonan Foley, Darren Martin Harvey, Michael John Munchhof, Michael Thomenius, Lawrence Alan Reiter
  • EZH2 inhibitors for treating lymphoma
    Patent number: 11951109
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: April 9, 2024
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah Kathleen Knutson, Danielle Johnston Blackwell
  • Methods of treating cancer by inhibiting SETD2
    Patent number: 11952572
    Abstract: The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancer, i.e., pancreatic cancer or esophageal cancer, by administering to a human subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: April 9, 2024
    Assignee: Epizyme, Inc.
    Inventors: Alexandra Rose Grassian, Michael Thomenius, Jennifer Anne Totman
  • CARM1 INHIBITORS AND USES THEREOF
    Publication number: 20230416263
    Abstract: Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.
    Type: Application
    Filed: November 23, 2022
    Publication date: December 28, 2023
    Applicant: Epizyme, Inc.
    Inventors: Richard Chesworth, Oscar Miguel Moradei, Gideon Shapiro, Lei Jin, Robert E. Babine
  • Carm1 inhibitors and uses thereof
    Patent number: 11834455
    Abstract: Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: December 5, 2023
    Assignee: Epizyme, Inc.
    Inventors: Richard Chesworth, Oscar Miguel Moradei, Gideon Shapiro, Lei Jin, Robert E. Babine
  • MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS
    Publication number: 20230357208
    Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: February 16, 2023
    Publication date: November 9, 2023
    Applicant: Epizyme, Inc.
    Inventors: Darren Martin Harvey, John Emmerson Campbell, Kenneth William Duncan
  • Use of EZH2 inhibitors for treating cancer
    Patent number: 11786533
    Abstract: The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: October 17, 2023
    Assignee: Epizyme, Inc.
    Inventors: Scott Ribich, Michael Thomenius
  • CARM1 INHIBITORS AND USES THEREOF
    Publication number: 20230279020
    Abstract: Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.
    Type: Application
    Filed: March 18, 2020
    Publication date: September 7, 2023
    Applicant: Epizyme, Inc.
    Inventors: Richard Chesworth, Oscar Miguel Moradei, Gideon Shapiro, Lei Jin, Robert E. Babine
  • MYST family histone acetyltransferase inhibitors
    Patent number: 11685732
    Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: June 27, 2023
    Assignee: Epizyme, Inc.
    Inventors: Darren Martin Harvey, John Emmerson Campbell, Kenneth William Duncan
  • Combination therapies with EHMT2 inhibitors
    Patent number: 11672800
    Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 13, 2023
    Assignee: Epizyme, Inc.
    Inventors: John Emmerson Campbell, Kenneth William Duncan, Maria Alejandra Raimondi, Christine Klaus, Elayne Penebre
  • Method for treating cancer
    Patent number: 11642349
    Abstract: The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: May 9, 2023
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah K. Knutson
  • Combination therapy for treating cancer
    Patent number: 11642346
    Abstract: The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: May 9, 2023
    Assignee: Epizyme, Inc.
    Inventors: Christine Klaus, Maria Alejandra Raimondi
  • Substituted benzene compounds
    Patent number: 11642348
    Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: May 9, 2023
    Assignee: Epizyme, Inc.
    Inventors: Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki, Syuji Shirotori, Wataru Itano, Wanjun Zheng
  • EZH2 inhibitors for treating lymphoma
    Patent number: 11642347
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: May 9, 2023
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Heike Keilhack, Sarah K. Knutson, Danielle Johnston Blackwell, Larisa Reyderman, Lone Ottesen